Riverhead Capital Management’s GSK GSK Stock Holding History

Riverhead Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-9,120	Closed	-$458K	–	1516
2018 Q3	$458K	Hold	9,120	–	–	0.02%	786
2018 Q2	$460K	Hold	9,120	–	–	0.02%	704
2018 Q1	$445K	Hold	9,120	–	–	0.02%	704
2017 Q4	$404K	Hold	9,120	–	–	0.02%	747
2017 Q3	$463K	Hold	9,120	–	–	0.02%	630
2017 Q2	$491K	Hold	9,120	–	–	0.02%	583
2017 Q1	$481K	Hold	9,120	–	–	0.03%	545
2016 Q4	$439K	Hold	9,120	–	–	0.03%	532
2016 Q3	$492K	Sell	9,120 -11,014	-55%	-$604K	0.03%	474
2016 Q2	$1.09M	Sell	20,134 -23,796	-54%	-$1.25M	0.04%	411
2016 Q1	$2.23M	Sell	43,930 -1,830	-4%	-$91.1K	0.03%	499
2015 Q4	$2.31M	Hold	45,760	–	–	0.03%	491
2015 Q3	$2.2M	Hold	45,760	–	–	0.03%	462
2015 Q2	$2.38M	Hold	45,760	–	–	0.04%	460
2015 Q1	$2.64M	Hold	45,760	–	–	0.04%	443
2014 Q4	$2.44M	Hold	45,760	–	–	0.04%	449
2014 Q3	$2.63M	Hold	45,760	–	–	0.05%	400
2014 Q2	$3.06M	Hold	45,760	–	–	0.06%	356
2014 Q1	$3.06M	Buy	+45,760	New	+$3.09M	0.07%	323
2013 Q3	–	Sell	-34,400	Closed	-$2.15M	–	434
2013 Q2	$2.15M	Buy	+34,400	New	+$2.18M	0.07%	261

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Riverhead Capital Management's GSK Position: Q4 2018 in Review

Riverhead Capital Management sold out of GSK (GSK) in Q4 2018, closing a stake of 9,120 shares — an estimated $458K sold.

Riverhead Capital Management first reported a position in GSK in Q2 2013 and held it in 20 quarters. The position peaked at $3.06M in Q2 2014. 799 funds tracked by Wall St. Rank hold GSK as of Q4 2018.

Riverhead Capital Management reported no remaining GSK position as of Q4 2018 after selling out during the quarter.
Riverhead Capital Management sold 9,120 GSK shares in Q4 2018, an estimated $458K.
Riverhead Capital Management first reported a position in GSK in Q2 2013 and held it in 20 quarters.
Riverhead Capital Management's GSK position peaked at $3.06M in Q2 2014.
799 funds tracked by Wall St. Rank held GSK as of Q4 2018.

Based on Riverhead Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.